Clinical trials: Sacubitril/Valsartan
Hypertension
Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension
To explore the efficacy of Sacubitril/Valsartan in the treatment of perimenopausal hypertensive patients, as well as the difference between the antihypertensive efficacy and valsartan, the therapeutic effect of its exposure to…
- Trial name
- NCT04800081
- Testing
- Sacubitril/Valsartan, Valsartan
- Where
- China
- Volunteers
- 264 people
- Sponsor
- LanZhou University
Heart Failure
Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before…
- Trial name
- NCT07347925
- Testing
- Prehospital ARNI use, No prehospital ARNI use
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Future University in Egypt
Sacubitril/Valsartan, Prosthetic Heart Valve
Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
- Conditions
- Sacubitril/Valsartan, Prosthetic Heart Valve, Heart Failure, Reduced Ejection Fraction
- Trial name
- NCT07192341
- Testing
- Sacubitril/Valsartan, Conventional anti-heart failure therapy
- Where
- Egypt
- Volunteers
- 220 people
- Sponsor
- Kafrelsheikh University
Heart Failure, Heart Dysfunction
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
- Trial name
- TREAT-HF (NCT05194111)
- Testing
- Sacubitril-valsartan, Valsartan, Carvedilol
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Virginia Commonwealth University
Congestive Heart Failure, Hypertension
Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
This pilot, feasibility study evaluates the efficacy of sacubitril-valsartan (Entresto) versus usual anti-hypertensive medications in patients with left ventricular assist devices (LVAD).
- Trial name
- NCT03279861
- Testing
- Entresto, Valsartan
- Sponsor
- University of Maryland, Baltimore
Heart Failure
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
The objective of this study is to evaluate whether valsartan/sacubitril leads to a superior improvement in endothelial function and endocrine status compared to valsartan alone.
- Trial name
- VASCEND (NCT03168568)
- Where
- Switzerland
- Volunteers
- 79 people
- Sponsor
- University of Zurich
Congenital Heart Disease, Heart Failure
" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
The treatment of adult patients with congenital heart disease (ACHD) and heart failure (HF) represents a great challenge since, to date, there is no standardized guideline for this specific population.
- Conditions
- Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT05580510
- Testing
- Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Empagliflozin 10 MG OD
- Where
- Mexico
- Volunteers
- 160 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Heart Failure With Reduced Ejection Fraction
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
The aim of this study was to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine…
- Trial name
- REACT-HFrEF-RO (NCT07465679)
- Where
- Romania
- Volunteers
- 2,508 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan
The aim of this study is to know if the Sacubitril-Valsartan treatment improves the T-wave alternans in those patients that begin its treatment, which would indirectly show a lower risk of malignant ventricular arrythmias.
- Trial name
- NCT04185103
- Testing
- Sacubitril-Valsartan
- Where
- 4 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Healthy Volunteers
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
To evaluate the bioequivalence between two formulations of sacubitril/valsartan 24 mg/26 mg film-coated tablets, Entresto 50 mg (Reference) and Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg (Test), after a single oral dose…
- Trial name
- NCT06193187
- Testing
- Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg, Entresto 50 mg
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories (Thailand) Limited
Systolic Hypertension
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).
- Trial name
- NCT01281306
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 90 sites in United States, Argentina and 7 more
- Volunteers
- 910 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
Angiotensin-neprilysin inhibitors (ARNI) are beneficial in patients with heart failure with reduced ejection fraction. No study evaluating ARNI has been conducted in sub-Saharan Africa (except South Africa) yet, where heart…
- Trial name
- NCT06704633
- Testing
- Sacubitril / Valsartan Oral Tablet
- Where
- Tanzania
- Volunteers
- 298 people
- Sponsor
- Martin Rohacek
Chronic Heart Failure
Special Drug Use Surveillance for Entresto Tablets
This is a single arm, multicenter, observational study in Japanese chronic heart failure patients.
- Trial name
- NCT04781881
- Testing
- Entresto
- Where
- 121 sites in Japan
- Volunteers
- 688 people
- Sponsor
- Novartis Pharmaceuticals
CKD5 Stage Dialysis, Heart Failure
Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
Hemodialysis or peritoneal dialysis CKD5 patients were randomly divided into Sacubitril/Valsartan and irbesartan treatment groups.
- Trial name
- NCT05243199
- Testing
- Sacubitril/Valsartan, Irbesartan
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Ruijin Hospital
Bioequivalence Study
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Primary objective is to is to evaluate the bioequivalence of two formulations
- Trial name
- NCT06273254
- Testing
- Sacubitril and Valsartan Tablets 49mg/51mg, Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Viatris Inc.
Atrial Fibrillation Recurrent, Hypertension
Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
Study name: Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation. Medicine: sacubitril/valsartan (100mg) and valsartan (80mg).
- Trial name
- NCT05528419
- Testing
- Sacubitril-valsartan, Valsartan
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
de Novo Heart Failure
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or…
- Trial name
- NCT05963282
- Where
- United States
- Volunteers
- 9,870 people
- Sponsor
- Novartis Pharmaceuticals
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of Sacubitril/Valsartan (Sac/Vals) compared to no initiation of the drug in patients with transthyretin cardiac amyloidosis…
- Trial name
- SAVA-TTR (NCT06712030)
- Testing
- Sacubitril / Valsartan
- Where
- Spain
- Volunteers
- 114 people
- Sponsor
- Puerta de Hierro University Hospital
Heart Failure, Systolic
Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
This proof-of-concept, open-label non-randomized clinical trial was conducted at a tertiary care cardiac center in Karachi, Pakistan.
- Trial name
- NCT05387967
- Testing
- Sacubitril/valsartan
- Where
- Pakistan
- Volunteers
- 121 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Heart Failure
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Prior to reperfusion therapy, the major therapeutic breakthrough in myocardial infarction was the demonstration that ACE inhibitors or ARBs, given to prevent adverse "remodelling" (progressive dilatation and decline in systolic…
- Trial name
- RECOVER-LV (NCT03552575)
- Testing
- sacubitril/valsartan, Valsartan
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people
- Sponsor
- NHS Greater Glasgow and Clyde